Bronchial Rheoplasty for Treatment of Chronic Bronchitis. Twelve-Month Results from a Multicenter Clinical Trial

Rationale: Chronic bronchitis (CB) is characterized by productive cough with excessive mucus production, resulting in quality-of-life impairment and increased exacerbation risk. Bronchial rheoplasty uses an endobronchial catheter to apply nonthermal pulsed electrical fields to the airways. Preclinical studies have demonstrated epithelial ablation followed by regeneration of normalized epithelium. Objectives: To evaluate the feasibility, safety, and initial outcomes of bronchial rheoplasty in patients with CB. Methods: Pooled analysis of two separate studies enrolling 30 patients undergoing bilateral bronchial rheoplasty was conducted. Follow-up through 6 months (primary outcome) and 12 months included assessment of adverse events, airway histology, and changes in symptoms using the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test and St. George’s Respiratory Questionnaire (SGRQ). Measurements and Main Results: Bronchial rheoplasty was performed in all 30 patients (63% male; mean [SD] age, 67 [7.4]; mean [SD] postbronchodilator FEV1, 65% [21%]; mean [SD] COPD Assessment Test score 25.6 [7.1]; mean [SD] SGRQ score, 59.6 [15.3]). There were no device-related and four procedure-related serious adverse events through 6 months, and there were none thereafter through 12 months. The most frequent nonserious, device- and/or procedure-related event through 6 months was mild hemoptysis in 47% (14 of 30) patients. Histologically, the mean goblet cell hyperplasia score was reduced by a statistically significant amount (P < 0.001). Significant changes from baseline to 6 months in COPD Assessment Test (mean, −7.9; median, −8.0; P = 0.0002) and SGRQ (mean, −14.6; median, −7.2; P = 0.0002) scores were observed, with similar observations through 12 months. Conclusions: This study provides the first clinical evidence of the feasibility, safety, and initial outcomes of bronchial rheoplasty in symptomatic patients with CB. Clinical trial registered with www.anzctr.org.au (ACTRN 12617000330347) and clinicaltrials.gov (NCT 03107494).

[1]  C. Schumann,et al.  Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial , 2019, American journal of respiratory and critical care medicine.

[2]  A. Valipour,et al.  Late Breaking Abstract - Bronchial Rheoplasty For Treatment of Chronic Bronchitis: 6 Month Results from a Prospective Multi-Center Study , 2019, Interventional pulmonology.

[3]  B. Nordestgaard,et al.  Prognostic significance of chronic respiratory symptoms in individuals with normal spirometry , 2019, European Respiratory Journal.

[4]  Daniel P Steinfort,et al.  First-in-Human Results of Bronchial Rheoplasty: An Endobronchial Treatment for Chronic Bronchitis (CB) , 2019, D94. COPD: EPIDEMIOLOGY AND THERAPY.

[5]  Meilan K. Han,et al.  Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy , 2019, Annals of the American Thoracic Society.

[6]  A. Valipour,et al.  Late Breaking Abstract - First-in-Human Results of Bronchial Rheoplasty: An Endobronchial Treatment For Chronic Bronchitis (CB) , 2018, Interventional Pulmonology.

[7]  Jae Seung Lee,et al.  Alternative definitions of chronic bronchitis and their correlation with CT parameters , 2018, International journal of chronic obstructive pulmonary disease.

[8]  C. Salome,et al.  Peripheral airway dysfunction and relationship with symptoms in smokers with preserved spirometry , 2018, Respirology.

[9]  K. Schoelles,et al.  Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma , 2017 .

[10]  D. Slebos,et al.  Safety and Histological Effect of Liquid Nitrogen Metered Spray Cryotherapy in the Lung. , 2017, American journal of respiratory and critical care medicine.

[11]  O. Franco,et al.  Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease , 2017, European Respiratory Journal.

[12]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. , 2017, American journal of respiratory and critical care medicine.

[13]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary , 2017, European Respiratory Journal.

[14]  K. Rabe,et al.  Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. , 2016, American journal of respiratory and critical care medicine.

[15]  J. Curtis,et al.  Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. , 2016, Annals of the American Thoracic Society.

[16]  Robert Paine,et al.  Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. , 2016, The New England journal of medicine.

[17]  D. Hansell,et al.  Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial , 2015, The Lancet.

[18]  R. Zuwallack,et al.  An official American Thoracic Society/European Respiratory Society statement: research questions in COPD , 2015, European Respiratory Review.

[19]  Thierry Troosters,et al.  An official American Thoracic Society/European Respiratory Society statement: research questions in COPD , 2015, European Respiratory Review.

[20]  V. Kim,et al.  Chronic Bronchitis and Current Smoking Are Associated with More Goblet Cells in Moderate to Severe COPD and Smokers without Airflow Obstruction , 2015, PloS one.

[21]  Grace Parraga,et al.  Using pulmonary imaging to move chronic obstructive pulmonary disease beyond FEV1. , 2014, American journal of respiratory and critical care medicine.

[22]  D. Lynch,et al.  Clinical and computed tomographic predictors of chronic bronchitis in COPD: a cross sectional analysis of the COPDGene study , 2014, Respiratory Research.

[23]  S. Kon,et al.  Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. , 2014, The Lancet. Respiratory medicine.

[24]  A. Husain,et al.  Endobronchial Biopsy: A Guide for Asthma Therapy Selection in the Era of Bronchial Thermoplasty , 2013, The Journal of asthma : official journal of the Association for the Care of Asthma.

[25]  V. Kim,et al.  Chronic bronchitis and chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[26]  P. Burgel.  Chronic cough and sputum production: a clinical COPD phenotype? , 2012, European Respiratory Journal.

[27]  Jordan F Baye.  Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. , 2012, P & T : a peer-reviewed journal for formulary management.

[28]  D. Slebos,et al.  Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial , 2011, The Lancet.

[29]  S. Guerra,et al.  Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk , 2009, Thorax.

[30]  D. Mannino,et al.  The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. , 2009, American journal of respiratory and critical care medicine.

[31]  Nicolas Roche,et al.  Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. , 2009, Chest.

[32]  P. Jones.  Health Status and the Spiral of Decline , 2009, COPD.

[33]  S. Lazarus,et al.  Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. , 2006, Chest.

[34]  A. Nissinen,et al.  Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. , 2006, Chest.

[35]  T. Sandström,et al.  Seven-year cumulative incidence of COPD in an age-stratified general population sample. , 2006, Chest.

[36]  P. Jones.  St. George's Respiratory Questionnaire: MCID , 2005, COPD.

[37]  C. Borror.  Nonparametric Statistical Methods, 2nd, Ed. , 2001 .

[38]  L. Fabbri,et al.  Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. , 2000, American journal of respiratory and critical care medicine.

[39]  J. Vestbo,et al.  Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. , 1996, American journal of respiratory and critical care medicine.

[40]  J. Bernaudin,et al.  Ciliary abnormalities in bronchial epithelium of smokers, ex-smokers, and nonsmokers. , 1995, American journal of respiratory and critical care medicine.

[41]  J. Hogg,et al.  Reassessment of inflammation of airways in chronic bronchitis. , 1985, British medical journal.

[42]  W. Thurlbeck,et al.  The National Institutes of Health Intermittent Positive-Pressure Breathing trial: pathology studies. II. Correlation between morphologic findings, clinical findings, and evidence of expiratory air-flow obstruction. , 1985, The American review of respiratory disease.

[43]  Philip H. Ramsey.  Nonparametric Statistical Methods , 1974, Technometrics.

[44]  D. Jarvis,et al.  Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. , 2007, American journal of respiratory and critical care medicine.